… 13 Aarden L, Ruuls SR, Wolbink GJ. Immunogenicity of antitumor necrosis factor
antibodies: towards improved methods of antiantibody measurement. Curr Op Imm 2008; 4:431–435 …

Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of
rheumatic diseases since their incorporation into treatment protocols two decades ago. …

Background Disease-specific studies have reported impaired humoral responses after
SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated with …

Background: Immunogenicity, specifically the onset of antibodies against tumour necrosis
factor (TNF) blocking agents, seems to play an important role in non-response to treatment …

Objective To study the usefulness of erythrocyte sedimentation rate (ESR), C‐reactive
protein (CRP), and serum amyloid A (SAA) for response prediction and monitoring of anti–tumor …

Rheumatoid factors are antibodies directed against IgG that may confound immunogenicity
testing for therapeutic monoclonal antibodies. We developed antigen-binding assays to …

Therefore, we studied the incidence of antiadalimumab antibodies in PsA, and the relationship
with serum adalimumab concentration and clinical response. Twenty-two patients with …

Human immunoglobulin G4 (IgG4) is a poor trigger of effector functions and, therefore, is the
preferred subclass for therapeutic monoclonal antibodies that merely aim to block their in …

Introduction The human monoclonal antibody adalimumab is known to induce an anti-globulin
response in some adalimumab-treated patients. Antibodies against adalimumab (AAA) …

Aim: For assessment of concentrations of biopharmaceuticals, for example, therapeutic drug
monitoring, dried blood sampling of capillary blood is a convenient alternative to traditional …